Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b

a technology of hepatitis b and arylamides, which is applied in the field of sulfamoylarylamides, can solve the problems of lack of selectivity, poor efficacy, and limited direct treatment options

Inactive Publication Date: 2015-10-01
JANSSEN SCI IRELAND UC
View PDF4 Cites 60 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

An effective and well-tolerated vaccine exists, but direct treatment options are currently limited to interferon and the following antivirals; tenofovir, lamivudine, adefovir, entecavir and telbivudine.
Amongst the problems which HBV direct antivirals may encounter are toxicity, mutagenicity, lack of selectivity, poor efficacy, poor bioavailability and difficulty of synthesis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010]The present invention relates to compounds of Formula (I)

or a stereoisomer or tautomeric form thereof, wherein:[0011]B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of 0, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C1-C3alkyl, CN, CFH2, CF2H and CF3;[0012]R1 represents hydrogen or C1-C3alkyl;[0013]R2 represents C1-C6alkyl, C1-C6alkenyl, C1-C6alkyl-R5, C(═O)—R5, CFH2, CF2H, CF3, a dihydro-indenyl or tetrahydronaphtalenyl moiety optionally substituted with OH, or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring, C1-C6alkyl-R5 or C1-C6alkyl optionally being substituted with one or more substituents each independen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Stop Timeaaaaaaaaaa
flow rateaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

Inhibitors of HBV replication of Formula (I)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Description

BACKGROUND ART[0001]The Hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA (dsDNA) virus of the Hepadnavirus family (Hepadnaviridae). Its genome contains 4 overlapping reading frames: the precore / core gene; the polymerase gene; the L, M, and S genes, which encode for the 3 envelope proteins; and the X gene.[0002]Upon infection, the partially double-stranded DNA genome (the relaxed circular DNA; rcDNA) is converted to a covalently closed circular DNA (cccDNA) in the nucleus of the host cell and the viral mRNAs are transcribed. Once encapsidated, the pregenomic RNA (pgRNA), which also codes for core protein and Pol, serves as the template for reverse transcription, which regenerates the partially dsDNA genome (rcDNA) in the nucleocapsid.[0003]HBV has caused epidemics in parts of Asia and Africa, and it is endemic in China. HBV has infected approximately 2 billion people worldwide of which approximately 350 million people have developed chronic infections. The virus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07C311/37A61K31/351A61K31/18C07D305/08A61K31/337A61K45/06A61K31/341A61K31/4453A61K31/55A61K31/401C07D491/107C07D205/04C07D309/14C07D307/22
CPCC07C311/37C07D309/14A61K31/351A61K31/18C07D305/08A61K31/337C07D307/22A61K31/341A61K31/4453A61K31/55A61K31/401C07D491/107C07D205/04A61K45/06A61K31/4164A61K31/426A61K31/44A61K31/4468C07C311/16C07C311/20C07C311/51C07D211/96C07D207/273C07D213/42C07D307/60C07D213/81C07D213/82C07D333/38C07D333/48C07D233/90C07D207/14C07D207/36C07D277/56C07D211/28C07D295/13C07D211/56C07D211/76C07D295/26C07D307/68C07C2601/02C07C2601/04C07C2601/08C07C2601/14C07C2602/08C07C2602/10A61K31/34A61K31/397A61K31/495A61K31/5375C07D223/06C07D233/84C07D493/08A61P1/16A61P1/18A61P31/12A61P31/20A61P43/00C07C311/15A61K31/335A61K31/381C07D231/14C07D213/04C07C311/14
Inventor VANDYCK, KOENLAST, STEFAAN JULIENROMBOUTS, GEERTVERSCHUEREN, WIM GASTONRABOISSON, PIERRE JEAN-MARIE BERNARD
Owner JANSSEN SCI IRELAND UC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products